Hmn-372 Now

Enter , a first‑in‑class, orally bioavailable small‑molecule inhibitor of the NLRP3 inflammasome —the multiprotein complex that converts danger signals into the pro‑inflammatory cytokines interleukin‑1β (IL‑1β) and IL‑18. By directly binding to the NLRP3 NACHT domain, HMN‑372 blocks ATP‑driven oligomerisation, curbing downstream caspase‑1 activation without impairing the host’s ability to respond to acute infection.